Copyright Reports & Markets. All rights reserved.

Global Induced Pluripotent Stem Cells (iPSCs) Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Induced Pluripotent Stem Cells (iPSCs) Market Overview

    • 1.1 Product Overview and Scope of Induced Pluripotent Stem Cells (iPSCs)
    • 1.2 Classification of Induced Pluripotent Stem Cells (iPSCs) by Types
      • 1.2.1 Global Induced Pluripotent Stem Cells (iPSCs) Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Types in 2018
      • 1.2.3 Human iPSCs
      • 1.2.4 Mouse iPSCs
    • 1.3 Global Induced Pluripotent Stem Cells (iPSCs) Market by Application
      • 1.3.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Academic Research
      • 1.3.3 Drug Development and Discovery
      • 1.3.4 Toxicity Screening
      • 1.3.5 Regenerative Medicine
    • 1.4 Global Induced Pluripotent Stem Cells (iPSCs) Market by Regions
      • 1.4.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) Induced Pluripotent Stem Cells (iPSCs) Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Induced Pluripotent Stem Cells (iPSCs) Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Induced Pluripotent Stem Cells (iPSCs) Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) Induced Pluripotent Stem Cells (iPSCs) Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Induced Pluripotent Stem Cells (iPSCs) Status and Prospect (2014-2024)
    • 1.5 Global Market Size of Induced Pluripotent Stem Cells (iPSCs) (2014-2024)

    2 Company Profiles

    • 2.1 Fujifilm Holding Corporation (CDI)
      • 2.1.1 Business Overview
      • 2.1.2 Induced Pluripotent Stem Cells (iPSCs) Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Fujifilm Holding Corporation (CDI) Induced Pluripotent Stem Cells (iPSCs) Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 ReproCELL
      • 2.2.1 Business Overview
      • 2.2.2 Induced Pluripotent Stem Cells (iPSCs) Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 ReproCELL Induced Pluripotent Stem Cells (iPSCs) Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Astellas Pharma Inc
      • 2.3.1 Business Overview
      • 2.3.2 Induced Pluripotent Stem Cells (iPSCs) Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Astellas Pharma Inc Induced Pluripotent Stem Cells (iPSCs) Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Ncardia
      • 2.4.1 Business Overview
      • 2.4.2 Induced Pluripotent Stem Cells (iPSCs) Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Ncardia Induced Pluripotent Stem Cells (iPSCs) Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Cell Inspire Biotechnology
      • 2.5.1 Business Overview
      • 2.5.2 Induced Pluripotent Stem Cells (iPSCs) Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Cell Inspire Biotechnology Induced Pluripotent Stem Cells (iPSCs) Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Sumitomo Dainippon Pharma
      • 2.6.1 Business Overview
      • 2.6.2 Induced Pluripotent Stem Cells (iPSCs) Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Sumitomo Dainippon Pharma Induced Pluripotent Stem Cells (iPSCs) Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Pluricell Biotech
      • 2.7.1 Business Overview
      • 2.7.2 Induced Pluripotent Stem Cells (iPSCs) Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Pluricell Biotech Induced Pluripotent Stem Cells (iPSCs) Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Fate Therapeutics, Inc
      • 2.8.1 Business Overview
      • 2.8.2 Induced Pluripotent Stem Cells (iPSCs) Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Fate Therapeutics, Inc Induced Pluripotent Stem Cells (iPSCs) Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Induced Pluripotent Stem Cells (iPSCs) Market Competition, by Players

    • 3.1 Global Induced Pluripotent Stem Cells (iPSCs) Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Induced Pluripotent Stem Cells (iPSCs) Players Market Share
      • 3.2.2 Top 10 Induced Pluripotent Stem Cells (iPSCs) Players Market Share
    • 3.3 Market Competition Trend

    4 Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Regions

    • 4.1 Global Induced Pluripotent Stem Cells (iPSCs) Revenue and Market Share by Regions
    • 4.2 North America Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 4.3 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 4.5 South America Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)

    5 North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Countries

    • 5.1 North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Countries (2014-2019)
    • 5.2 USA Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 5.3 Canada Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)

    6 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Countries

    • 6.1 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Countries (2014-2019)
    • 6.2 Germany Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 6.3 UK Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 6.4 France Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 6.5 Russia Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 6.6 Italy Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Revenue by Countries

    • 7.1 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Revenue by Countries (2014-2019)
    • 7.2 China Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 7.3 Japan Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 7.4 Korea Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 7.5 India Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)

    8 South America Induced Pluripotent Stem Cells (iPSCs) Revenue by Countries

    • 8.1 South America Induced Pluripotent Stem Cells (iPSCs) Revenue by Countries (2014-2019)
    • 8.2 Brazil Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue Induced Pluripotent Stem Cells (iPSCs) by Countries

    • 9.1 Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 9.3 UAE Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa Induced Pluripotent Stem Cells (iPSCs) Revenue and Growth Rate (2014-2019)

    10 Global Induced Pluripotent Stem Cells (iPSCs) Market Segment by Type

    • 10.1 Global Induced Pluripotent Stem Cells (iPSCs) Revenue and Market Share by Type (2014-2019)
    • 10.2 Global Induced Pluripotent Stem Cells (iPSCs) Market Forecast by Type (2019-2024)
    • 10.3 Human iPSCs Revenue Growth Rate (2014-2024)
    • 10.4 Mouse iPSCs Revenue Growth Rate (2014-2024)

    11 Global Induced Pluripotent Stem Cells (iPSCs) Market Segment by Application

    • 11.1 Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Application (2014-2019)
    • 11.2 Induced Pluripotent Stem Cells (iPSCs) Market Forecast by Application (2019-2024)
    • 11.3 Academic Research Revenue Growth (2014-2019)
    • 11.4 Drug Development and Discovery Revenue Growth (2014-2019)
    • 11.5 Toxicity Screening Revenue Growth (2014-2019)
    • 11.6 Regenerative Medicine Revenue Growth (2014-2019)

    12 Global Induced Pluripotent Stem Cells (iPSCs) Market Size Forecast (2019-2024)

    • 12.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Size Forecast (2019-2024)
    • 12.2 Global Induced Pluripotent Stem Cells (iPSCs) Market Forecast by Regions (2019-2024)
    • 12.3 North America Induced Pluripotent Stem Cells (iPSCs) Revenue Market Forecast (2019-2024)
    • 12.4 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Revenue Market Forecast (2019-2024)
    • 12.6 South America Induced Pluripotent Stem Cells (iPSCs) Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Description

      Scope of the Report:
      The global Induced Pluripotent Stem Cells (iPSCs) market is valued at 74 million USD in 2018 and is expected to reach 114.9 million USD by the end of 2024, growing at a CAGR of 11.7% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Induced Pluripotent Stem Cells (iPSCs).
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the Induced Pluripotent Stem Cells (iPSCs) market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Induced Pluripotent Stem Cells (iPSCs) market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      Fujifilm Holding Corporation (CDI)
      ReproCELL
      Astellas Pharma Inc
      Ncardia
      Cell Inspire Biotechnology
      Sumitomo Dainippon Pharma
      Pluricell Biotech
      Fate Therapeutics, Inc

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Human iPSCs
      Mouse iPSCs

      Human iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs.

      Market Segment by Applications, can be divided into
      Academic Research
      Drug Development and Discovery
      Toxicity Screening
      Regenerative Medicine

      Academic Research is the largest segment of Induced Pluripotent Stem Cells (iPSCs) application,with a share of 32% in 2018.

      Buy now